Ingredients and methods for treating cancer include managing combinations of antineoplastic agents, including carcinogenic molecular therapeutics and one or more nucleic acid molecules that can negatively regulate the surface layer. There is at least one conjugate variant of Ig20 gene, not all of which are unfavourably regulated. In one implementation, the paired variant of Ig20 is Madd, while the nucleic acid molecule is Siam.RNHC and Oligodeoxyribonucleic acid are complements to the nucleic acid sequence of foreign 13L adds or RNM converters of foreign 13L adds. Treatment of cancer, using combination therapy with nucleic acid molecules, can be negatively regulated.Exposure to at least one Ig20 gene conjugation variant and pathogenic-inducing molecular therapeutic agent. Requirement 1: Combination of antineoplastic agents for cancer treatment, including an effective number of one or more nucleic acid molecules, can reduce the expression of at least one cutting variant and Ig20 binding.Here, all forms of expression for IG20 cutting and binding, as well as one or more carcinogenic molecular pathogens. 7. Requirement 7: Consolidation Requirement 6, in which RNAPI and RNHP are numbered by a nucleic acid molecule including structure X 834783378345； 83488305； 7496； 833838-Bucle Hornique-X-8336838383838345； 834883830583478345； 83484848838383838383838383833838；X consists of or basically consists of CGCAATCTATCATC (SEQ ID No.1) nucleic acid sequences. Claim 13: Consolidated claim 12, that is, the drug management system is a directed lipid solution formulation or a chronic vector. Claim 14: Mixture of Claim 1, i.e. the selection of one or more pathogenic molecular therapeutics from lnterlequine 2 (LL2),Interference-A (IFN-A) and induced ligation associated with tumor necrosis factor A (TRAIL) lead to premature aging.Composiciones y métodos para tratar canceres, que comprenden administrar una combinación de agentes antineoplásicos, donde la combinación comprende agentes terap
